Holen Sie sich die Stockscreener-App
11.59
0.86%
-0.10
Schlusskurs vom Vortag:
$11.69
Offen:
$11.69
24-Stunden-Volumen:
840.57K
Relative Volume:
0.86
Marktkapitalisierung:
$684.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-3.1409
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
-5.23%
1M Leistung:
+8.01%
6M Leistung:
+51.70%
1J Leistung:
+20.86%
1-Tages-Spanne:
$11.40
$12.18
1-Wochen-Bereich:
$11.36
$12.55
52-Wochen-Spanne:
$5.68
$13.43
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
11.59 | 690.60M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
US Market Wrap: What’s the RSI of Cullinan Therapeutics Inc. stockWeekly Trade Recap & High Conviction Buy Zone Picks - mfd.ru
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Exploring A 159.97% Potential Upside - DirectorsTalk Interviews
What is Cullinan Therapeutics Inc.’s valuation compared to sectorQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
Can Cullinan Therapeutics Inc. ride the EV wave2025 Year in Review & Safe Capital Growth Plans - mfd.ru
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum - MarketBeat
CGEM: 2026 will deliver key data for T cell engagers in autoimmune and AML, driving major portfolio catalysts - TradingView
Retail Trends: Whats the profit margin of Cullinan Therapeutics IncProduct Launch & Intraday High Probability Alerts - baoquankhu1.vn
What is the long term forecast for Cullinan Therapeutics Inc. stockQuarterly Trade Summary & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Exploring a Promising 148.86% Upside in Biotech - DirectorsTalk Interviews
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Guggenheim Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Strong-Buy - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month HighTime to Buy? - MarketBeat
Guggenheim Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CGEM with a 'Buy' Rating | CGEM Stock News - GuruFocus
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com - Investing.com UK
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
Aug Patterns: What drives Cullinan Therapeutics Incs stock price2025 Pullback Review & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Levels Update: What drives Cullinan Therapeutics Incs stock priceMarket Weekly Review & Low Risk High Reward Ideas - baoquankhu1.vn
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Cullinan Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth? - Sahm
Cullinan Therapeutics (NASDAQ:CGEM) Cut to "Sell" at Wall Street Zen - MarketBeat
Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91 - MSN
Insider Sell: Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc (CGEM) - GuruFocus
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Gainers Report: Can Cullinan Therapeutics Inc outperform under higher oil prices2025 Support & Resistance & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Yahoo Finance
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 10.6%Here's Why - MarketBeat
History Review: What is the Moat Score of Cullinan Therapeutics IncIPO Watch & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Cullinan Therapeutics Inc benefit from AI trends2025 Market WrapUp & Risk Controlled Swing Alerts - baoquankhu1.vn
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Published on: 2026-01-11 22:17:06 - ulpravda.ru
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones - Yahoo Finance
Market Fear: Will Cullinan Therapeutics Inc. stock split again soonWeekly Stock Report & Real-Time Volume Triggers - ulpravda.ru
Will Cullinan Therapeutics Inc. stock split again soonProfit Target & Weekly Return Optimization Alerts - ulpravda.ru
How strong is Cullinan Therapeutics Inc. stock balance sheetQuarterly Trade Review & Reliable Breakout Stock Forecasts - ulpravda.ru
Today's Analyst Ratings Update: CGEM Price Target Raised to $27 - GuruFocus
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook - TipRanks
Cullinan Therapeutics (CGEM) Outlines Key Developments for 2026 - GuruFocus
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com - Investing.com Australia
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):